Akamis Bio
1 known investors
Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life. The company serves patients and clinicians in the oncology market.
BiotechDigital HealthHealthtechMedical Devices
Investors · 1
In the news
- Akamis Bio Raises $60 Million for Cancer Gene Therapy, Signs Licensing Deal with Xuanzhu Biopharmagenengnews.com · 2024
- Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnershipbusinesswire.com · 2024
- Akamis Bio Raises $60M in Fundingfinsmes.com · 2024
- Akamis Bio - 2025 Company Profile, Funding, Competitors & Financials - Tracxntracxn.com · 2023